July 29, 2025

Impact of Long-Term Use of Sglt2 Inhibitors in Patients With Heart Failure: A Review Based on Clinical Studies

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Narrative review highlights SGLT2 inhibitors improve ejection fraction and reduce cardiovascular mortality in heart failure patients.

Main finding shows SGLT2 inhibitors significantly reduce hospitalizations and cardiovascular mortality in heart failure.
Key evidence from studies like DAPA-HF and EMPEROR-Reduced confirms their efficacy across different ejection fraction profiles.
Approach involved systematic literature search for studies published from 2019 to 2024 on SGLT2 inhibitors' long-term effects.
Significance lies in improved cardiac function, renal protection, and quality of life for heart failure patients.

Vieira et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark